Who
Fred Aslan
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Artiva Biotherapeutics.
In numbers
- Trades disclosed
- 37
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $3.2M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 18 Jul 2024
- Last trade
- 6 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Aug 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 7 Oct 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $169K23,463 at $7.20 | filing |
| 5 Oct 2026filed 6 Oct 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $422K61,696 at $6.84 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —315,000 at $0.00 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —315,000 at $0.00 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 8 Sep 2026filed 9 Sep 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $256K23,429 at $10.92 | filing |
| 8 Sep 2026filed 9 Sep 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $256K23,429 at $10.92 | filing |
| 3 Sep 2026filed 4 Sep 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $690K61,888 at $11.16 | filing |
| 3 Sep 2026filed 4 Sep 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $691K61,888 at $11.16 | filing |
| 19 May 2026filed 19 May 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $244K27,116 at $9.01 | filing |
| 19 May 2026filed 19 May 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $244K27,116 at $9.01 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —366,850 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $58K14,600 at $4.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —366,850 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $58K14,600 at $4.00 | filing |
News
No headline names them, or the companies they trade most, lately.